Diagnostic and therapeutic procedures in pheochromacytoma: current trends

Česká verzia

Authors: J. Widimský Jr ¹; T. Zelinka ¹; O. Petrák ¹; B. Štrauch ¹; L. Šafařík ²; M. Kasalický ³; A. Vranková ¹; R. Holaj ¹
Authors place of work: Centrum pro hypertenzi III. interní kliniky 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA ¹; Urologická klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Jan Dvořáček, DrSc. ²; I. chirurgická klinika 1. lékařské fakulty UK a VFN Praha, přednosta doc. MUDr. Jan Šváb, CSc. ³
Published in the journal: Vnitř Lék 2007; 53(4): 428-433
Category: Reviews

Summary

Pheochromacytoma is a relatively rare cause of arterial hypertension. Untreated pheochromacytoma may however lead to a fatal hypertensive crisis during anaesthesia or another form of stress. It is therefore important to correctly diagnose this disease. 24-hour monitoring of blood pressure (BP) can already contribute to the diagnosis of pheochromacytoma based on the frequent occurrence of BP variability and the absence of a night-time fall in BP. 5 gene mutations have so far been identified that may be responsible for the familial form of pheochromacytoma: mutation of the von Hippel-Lindau (VHL) gene, leading to the onset of VHL syndrome, mutation of the RET-proto-oncogene in multiple endocrine adenomatosis type 2, mutation of the type 1 gene for neurofibromatosis, which is associated with von Recklinghausen’s disease and finally mutation of the genes encoding the B and D subunits of succinate dhydrogenase (SDHB, SDHD), which are associated with familial paragangliomas and pheochromacytoma. Genetic analysis should therefore be carried out for all confirmed cases of pheochromacytoma, especially for young people under 50 years of age. Biochemical diagnostics relies mainly on measurements of free metanephrines in plasma or urine, which usually has greater diagnostic weight than plasma, or catecholamines in urine. The diagnosis of extraadrenal or multiple forms can use not only CT/MR but also imaging using the radiopharmaceutical 123I-Metaiodobenzylguanidine (MIBG) or 18F-fluorodopamine PET (only available in the USA). Pharmacological treatment using alpha or beta receptor blockers with subsequent laparoscopic excision of the tumor is usually successful in benign forms of pheochromocytoma. Unfortunately, there are still no convincingly effective therapeutic procedures available for malign forms.

Key words:
pheochromacytoma – blood pressure – genetic analysis – diagnostics – treatment

Zdroje

1. McNeil AR, Blok BH, Koelmeyer TD et al. Phaeochromocytoma discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust NZ J Med 2000; 30: 648-652.

2. Strauch B, Zelinka T, Hampf M et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertension 2003; 17: 349-352.

3. Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep 2004; 6: 477-484.

4. Kaplan NM. Clinical hypertension. Philadelphia: Lippincott, Williams&Wilkins 2006: 1-518.

5. Zelinka T, Štrauch B, Pecen L et al. Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing’s syndrome. J Human Hypertension 2004; 18: 107-111.

6. Zelinka T, Widimský J jr, Weisserová J. Diminished circadian blood pressure rhytm in patients with asymptomatic normotensive pheochromocytoma. Physiol Res 2001; 50: 631-634.

7. Kikuya M, Hozawa T, Ohkubo T et al. Prognostic significance of blood pressure and heart rate variabilities. The Ohasama study. Hypertension 2000; 36: 901-906.

8. Zelinka T, Štrauch B, Petrák O et al. Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. J Hypertens 2005; 23: 2033-2039.

9. Neumann HP, Bausch B, Mc-Whinney SR et al. for the Freiburg-Warshaw-Columbus Pheochromocytoma Study Group. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346: 1459-1466.

10. Lenders JWM, Eisenhofer G, Mannelli M et al. Pheochromocytoma. Lancet 2005; 366: 665-675.

11. Amar L, Bertherat J, Baudin E et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005; 23: 8812-8818.

11. Eisenhofer G, Bornstein SR, Brouwers FM et al. Malignant pheochromocytoma. Current status and initiatives for future progress. Endocr Rel Cancer 2004; 11: 423-436.

12. Eisenhofer G, Keiser H, Friberg P et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998; 83: 2175-2185.

13. Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287: 1427-1434.

14. Goldstein DS, Eisenhofer G, Flynn JA et al. Diagnosis and localisation of pheochromocytoma. Hypertension 2004; 43: 907-910.

15. Bravo EL, Tagle R Pheochromocytoma: state of the art and future prospects. Endocr Rev 2003; 24: 539-553.

16. Kudva YC, Sawka AM, Young WF jr et al. The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003; 88: 4533-4539.

17. Bravo EL, Tarazi RC, Fouad FM et al. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981; 305: 623-626.

18. Eisenhofer G, Goldstein DS, Walther MM et al. Biochemical diagnosis of pheochromocytoma: how to distinquish true-from false positive results. J Clin Endocrinol Metab 2003; 88: 2656-2666.

19. Mukherjee JJ, Peppercorn PD, Reznek RH et al. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology 1997; 202: 227-231.

19. Pacak K, Eisenhofer G, Carrasquillo JA et al. 6-(18F)fluorodopamine positron emission tomographic (PET) scanning for diagnostic localisation of pheochromocytoma. Hypertension 2001; 38: 6-8.

20. Ilias I, Pacak K Current approaches and recommended algorithm for the diagnostic localisation of pheochromocytoma. J Clin Endocrinol Metab 2004; 89: 479-491.

21. Prys-Roberts C Pheochromocytoma - recent progress in its management. Br J Anaesth 2000; 85: 44-57.

22. Janetschek G, Finkenstdt G, Gasser R et al. Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol 1998; 160: 330-334.

23. Sprung J, O’Hara JF jr, Gill IS et al. Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma. Urology 2000; 55: 339-343.

24. Plouin PF, Chatellier G, Fofol I et al. Tumour recurrence and hypertension persistance after successful pheochromocytoma operation. Hypertension 1997; 29: 1133-1139.

25. Rose B, Matthay KK, Price D et al. High-dose 131I-MIBG therapy for 12 patients with malignant pheochromocytoma. Cancer 2003; 98: 239-248.